The overall 5-year survival for pancreatic cancer has changed little over the past few
decades, and pancreatic cancer is predicted to be the second leading cause of cancer …

Pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of all
pancreatic tumours, is a devastating malignancy with an extremely poor prognosis, as …

Cancer-associated fibroblasts (CAFs) comprise the majority of the tumor bulk of pancreatic
ductal adenocarcinomas (PDACs). Current efforts to eradicate these tumors focus …

Pancreatic cancer is a major cause of cancer-associated mortality, with a dismal overall
prognosis that has remained virtually unchanged for many decades. Currently, prevention or …

Stromal responses elicited by early stage neoplastic lesions can promote tumor growth.
However, the molecular mechanisms that underlie the early recruitment of stromal cells to …

Inherent difficulties with blocking many desirable targets using conventional approaches
have prompted many to consider using RNA interference (RNAi) as a therapeutic approach …

Pancreatic cancer is a very aggressive disease characterized by a marked desmoplasia with
a predominant Th2 (GATA-3+) over Th1 (T-bet+) lymphoid infiltrate. We found that the ratio …

We have identified a new role for the matrix enzyme lysyl oxidase–like-2 (LOXL2) in the
creation and maintenance of the pathologic microenvironment of cancer and fibrotic …

Background Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause of
cancer related death. It is lethal in nearly all patients, due to an almost complete …

Pancreatic cancer remains a lethal malignancy with poor prognosis owing to therapeutic
resistance, frequent recurrence and the absence of treatment strategies that specifically …